A Europe-based impact fund is investing from an evergreen fund. The firm is focused on investing in pre-clinical companies in pre-seed and seed rounds. The firm particularly likes companies with an IP component – patent or patent pending. The typical check size is 100K-500K euros, and the firm is looking to make 7-10 investments within the next year. The firm typically acts as a syndicate, not usually leading rounds. The firm will invest globally, with a particular focus on the USA and Europe.
The firm invests in two main verticals – human preservation and planet health. Within life sciences, the firm invests primarily in therapeutics and biopharma, and will invest in diagnostics, medical devices, and digital health. The firm likes to look at companies offering a unique factor, such as specialized biopharma or drug delivery mechanism. The firm has a particular focus on CNS, oncology, and alternative cell therapies.
The firm has no specific team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment